Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents.

Leukemia research - 1 Jul 2022

Chauvet Paul, Nibourel Olivier, Berthon Celine, Goursaud Laure, Carpentier Benjamin, Lionne-Huyghe Pauline, Wemeau Mathieu, Quesnel Bruno

Abstract excerpt

Subsequent blast (BP) or accelerated phase (AP) is a severe complication of Philadelphia-negative myeloproliferative neoplasms (MPNs). The prognosis is generally dismal, but hypomethylating agents (HMAs) may induce a long-lasting response in a minority of patients. Here, we report a cohort of six patients with BP/AP-MPN who experienced MPN relapse after a leukemia response was obtained with azacytidine. Five of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azacitidine
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Leukemia

Share to Lymphocyte Activation

Share to Mutation

Share to Myeloproliferative Disorders

Share to Neoplasms

Share to Recurrence

Source

Identifiers

PMID: 35633618
DOI: 10.1016/j.leukres.2022.106871

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents.PMID 35633618Read ↗

Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?Semantic proximity Read ↗

Accelerated Phase of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts.Semantic proximity Read ↗

A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.Semantic proximity Read ↗

Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome.Semantic proximity Read ↗

What are the molecular mechanisms driving the switch from MPNs to leukemia?Semantic proximity Read ↗

Accelerated and Blast Phase Myeloproliferative Neoplasms.Semantic proximity Read ↗

Blast Phase of Myeloproliferative Neoplasm Resembles Acute Myeloid Leukemia, Myelodysplasia-Related, in Clinical Presentation, Cytogenetic Pattern, and Genomic Profile, and Often Undergoes Reversion to Second Chronic Phase Status After Induction Chemotherapy.Semantic proximity Read ↗

Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasmSemantic proximity Read ↗

Outcome of patients with accelerated and blast‐phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination—A FIM studySemantic proximity Read ↗

TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.